Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13944389 | 0.84 | SRD5A2 (0.57) | MGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL13657578 | 0.84 | MGLL (0.71) | MGLLLMNATP53MAPTL3MBTL1 | |
| SCHEMBL28203216 | 0.84 | KMT2A (0.71) | MGLLLMNAMEN1KMT2AHSD11B1 | |
| SCHEMBL8155672 | 0.84 | KDM2B (0.71) | MGLLLMNATP53MAPTL3MBTL1 | |
| SCHEMBL21775932 | 0.83 | MGLL (0.59) | MGLLLMNATP53MAPTL3MBTL1 | |
| (4-Chlorophenyl)(Cyclopropyl)Methanone SCHEMBL392801 | 0.83 | MGLL (0.68) | MGLLLMNATP53MAPTL3MBTL1 | |
| SCHEMBL3391936 | 0.83 | HSD11B1 (0.69) | MGLLHSD11B1 | |
| SCHEMBL8081266 | 0.83 | MGLL (0.60) | MGLLLMNATP53MAPTL3MBTL1 | |
| SCHEMBL10112201 | 0.83 | HSD11B1 (0.60) | MGLLMEN1KMT2AHSD11B1 | |
| SCHEMBL13391008 | 0.83 | HRH4 (0.51) | MGLLLMNATP53MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1784401-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-05-16 | — | — | EP | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006024160-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-03-09 | — | — | WO | disclosed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-5998412-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | MGLL 3161/4885LMNA 370/4885TP53 237/4885 |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | ORAI1, ATP2A1, CACNA1B | MGLL 3858/4885LMNA 1657/4885TP53 2315/4885 |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | DRD3, DRD2, HTR3C | MGLL 3906/4885LMNA 3938/4885TP53 4562/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | MGLL 4028/4885LMNA 4087/4885TP53 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.